福瑞股份跌2.07%，成交额7440.23万元，主力资金净流出1003.68万元

Core Viewpoint - Furuya Co., Ltd. has experienced significant stock price fluctuations and a notable increase in revenue and profit year-to-date, indicating a positive growth trajectory in the medical and pharmaceutical sector [1][2]. Group 1: Stock Performance - On November 4, Furuya's stock price decreased by 2.07%, trading at 72.55 CNY per share, with a total market capitalization of 19.22 billion CNY [1]. - Year-to-date, Furuya's stock price has increased by 130.03%, with a 3.45% rise over the last five trading days, a 4.16% decline over the last 20 days, and a 65.53% increase over the last 60 days [1]. - The company has appeared on the trading leaderboard twice this year, with the most recent instance on September 15, where it recorded a net buy of 74.25 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Furuya achieved a revenue of 1.101 billion CNY, reflecting a year-on-year growth of 12.37%, and a net profit attributable to shareholders of 112 million CNY, up by 9.69% [2]. - Cumulative cash dividends since the A-share listing amount to 246 million CNY, with 52.61 million CNY distributed over the past three years [3]. Group 3: Shareholder Structure - As of September 30, 2025, Furuya had 26,700 shareholders, an increase of 3.24% from the previous period, with an average of 8,742 circulating shares per shareholder, down by 3.09% [2]. - The top ten circulating shareholders include notable entities such as Huabao Zhongzheng Medical ETF and Ruiyuan Growth Value Mixed A, with some shareholders reducing their holdings while new shareholders have entered [3].